Tokuyama announced a policy of raising revenue from its diagnostics business to ¥35 billion in fiscal 2030, an increase of approximately 75% from fiscal 2025.
At a briefing, Tokuyama said it would position the diagnostics business of its Life Science segment as a growth driver and raise revenue to ¥35 billion in fiscal 2030.
The diagnostics business, centered on diagnostic reagents and testing equipment, is positioned as a key pillar for accelerating growth within the Life Science segment.
Life Science revenue was ¥49.4 billion in fiscal 2025, with the diagnostics business accounting for 40% of the segment’s revenue mix. The business has been strengthened through a series of M&A transactions.
The company said it aims to expand the business in Europe and the United States, China, India and Southeast Asia.